Ad Astra Diagnostics receives 510(k) clearance of QScout(TM) hematology analyzer, the first to report measures of infection and severity at point-of-care

QScout™ RLD is the first test to report at point-of-care infection-fighting immature granulocytes (IGs), an early marker of sepsis, and neutrophil-to-lymphocyte ratio (NLR), a prognostic marker for several diseases including COVID-19 MORRISVILLE, N.C., ... Diagnostics, FDA Ad Astra Diagnostics, QScout
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news